Nektar Therapeutics's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 90 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 153.25.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Nektar Therapeutics is 6.10, ranking 282 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 10.86M, representing a year-over-year increase of 3.83%, while its net profit experienced a year-over-year increase of 11.75%.
Key Metrics
The current valuation score of Nektar Therapeutics is 6.87, ranking 198 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -8.91, which is -99.82% below the recent high of -0.02 and -15.96% above the recent low of -10.34.
The current earnings forecast score of Nektar Therapeutics is 8.80, ranking 55 out of 382 in the Biotechnology & Medical Research industry. The average price target is 105.00, with a high of 121.00 and a low of 98.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Nektar Therapeutics is 6.78, ranking 155 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 96.62 and the support level at 57.00, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Nektar Therapeutics is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 61.39%, representing a quarter-over-quarter decrease of 16.36%. The largest institutional shareholder is Steven Cohen, holding a total of 433.42K shares, representing 1.28% of shares outstanding, with 1.00% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Nektar Therapeutics is 4.35, ranking 86 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.21. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Nektar Therapeutics’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
